This contract expires in 166 days (Sep 30, 2026).
FIRM FIXED PRICE
BRISTOL-MYERS SQUIBB COMPANY - MAVACAMTEN (CAMZYOS) AND POMALIDOMIDE (POLMALYST)
PIID: 36C24526N0290
Signed Date: Feb 11, 2026Effective Date: Jan 29, 2026End Date: Closes in 166 days
Key Details
Description
MAVACAMTEN (CAMZYOS) AND POMALIDOMIDE (POLMALYST)
Contractor Information
Contractor: BRISTOL-MYERS SQUIBB COMPANY
UEI: UFGKB2B71N12
CAGE Code: 4K2D9
Location: LAWRENCEVILLE, NJ
Similar Awards
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
MCKESSON CORPORATION
$1.4B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
MCKESSON CORPORATION
$1.2B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER
MCKESSON CORPORATION
$1.1B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY
MCKESSON CORPORATION
$1.1B
LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC.
EXELAN PHARMACEUTICALS INC
$5.1M
Stay Updated
Get notified about new opportunities matching your interests.